Jazz Pharmaceuticals plc (JAZZ)
$210.39-2.93%Close
SELLBEAR · day 32
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $13.2B
- Beta
- 0.32
- P/E (TTM)
- 13.84
- Short % float
- 9.01%
- Days to cover
- 6.5
- SI change
- +17.2%
- 1W
- -9.08%
- 1M
- -14.43%
- vs SPY 1W
- -8.94%
- vs SPY 1M
- -16.94%
Industry peers
FMP comparable companies · ranked by market cap
- UCBJFUCB S.A.$45.1B$236.94
- INCYSELLIncyte Corporation$22.9BBEARQ 13$112.79-2.46%
- GMABBUYGenmab A/S$22.8BBULLQ 21$37.07-2.14%
- NBIXSELLNeurocrine Biosciences, Inc.$14.3BRECOVERYQ 16$142.44-4.41%
- TGTXSELLTG Therapeutics, Inc.$8.5BBEARQ 11$55.37-1.68%
- LGNDBUYLigand Pharmaceuticals Incorporated$6.0BRECOVERYQ 15$301.81-2.44%
- SHJBFShanghai Junshi Biosciences Co., Ltd.$4.8B$3.35
- LEGNSELLLegend Biotech Corporation$3.4BRECOVERYQ 2$18.62+0.45%
- HRMYSELLHarmony Biosciences Holdings, Inc.$2.3BBEARQ -0$40.28-3.14%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on JAZZ?
- LOPJLB’s latest quantitative signal on Jazz Pharmaceuticals plc (JAZZ) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is JAZZ in?
- Jazz Pharmaceuticals plc (JAZZ) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Jazz Pharmaceuticals plc (JAZZ) do?
- Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TS…